Is the price fair?
What A's price assumes
Agilent Technologies trades at 29.0× earnings against 33.6× for the median Diagnostics & Research name, cheaper than its own group.
29.0
Trailing P/E · Diagnostics & Research median 33.6 · cheaper than the typical name in its group
- Price / sales
- 4.52
Price / sales · as of 2026-Q2
- Free cash flow yield
- 3.5%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; the business has delivered −3.7% a year over the last three.
Details›
- Price / book2026-Q2
- 4.59
- EV / EBIT2026-Q2
- 21.8
- EV / sales2026-Q2
- 4.69
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $1.27B
- Market capitalisation
- $35.9B
- 3-year revenue growth
- +1.8%
- 3-year free cash flow growth
- −3.7%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $147.89 |
| Its own P/E history, median | $157.68 |
| Its own P/E history, upper quartile | $206.30 |
| 52-week range | $109.99 – $160.00 |
| Today | $146.81 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry